Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood.

This research study involves the following investigational drugs:

* Sacituzumab govitecan
* Atezolizumab
Breast
II
Abramson, Vandana
NCT04434040
VICCBRE2056

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Multiple Cancer Types

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Germ Cell (Pediatrics), Gynecologic, Ovarian
III
Borinstein, Scott
NCT03067181
COGAGCT1531

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Multiple Cancer Types

Head/Neck, Phase I
I
Rosenthal, Eben
VICCHNP24602

Pilot Study Assessment of Bone Mineral Density Changes During Treatment with Anti-PD-1 Immunotherapy Agents

Miscellaneous

Miscellaneous
N/A
Sharpe, Jessica
VICCMD25019


High-Resolution Specimen PET-CT Imaging for the Intraoperative Visualization of Resection Margins: An Exploratory Study

Miscellaneous

Miscellaneous
I
Topf, Michael
VICCHNP24616

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.